How the 90% Confidence Interval Rule Shapes Bioequivalence Decisions

Introduction: The Role of Statistics in Bioequivalence

In bioavailability and bioequivalence (BA/BE) studies, demonstrating therapeutic equivalence between a generic and a reference drug is a regulatory cornerstone. Among various statistical tools, the 90% confidence interval (CI) rule is the universally accepted method for assessing bioequivalence. Regulatory bodies such as the FDA, EMA, and CDSCO require that the 90% CI of the pharmacokinetic parameter ratios—such as C_max and AUC—fall within a defined equivalence margin to be deemed bioequivalent.

This tutorial breaks down the theory and application of the 90% CI rule, using real-world examples and practical calculations for pharmaceutical and clinical professionals.

Why the 90% Confidence Interval and Not 95%?

In typical hypothesis testing, a 95% CI is used to determine significance. However, in BA/BE studies, the objective is not to show a difference but to demonstrate equivalence. This leads to the use of the Two One-Sided Tests (TOST) procedure, where two one-sided 5% tests are applied. The result is a 90% CI that must fall entirely within the regulatory acceptance limits—usually 80.00% to 125.00% on a log-transformed scale.

Statistical Foundation of the 90% CI Rule

The 90% confidence interval is calculated around the geometric mean ratio (GMR) of key pharmacokinetic parameters. These typically include:

• C_max: Maximum plasma concentration
• AUC_0-t: Area under the curve to the last measurable concentration
• AUC_0-∞: Area under the curve extrapolated to infinity

All parameters are log-transformed prior to analysis to stabilize variances and improve normality, which is a key assumption in parametric statistics.

Step-by-Step Calculation of 90% Confidence Interval

Below is a simplified workflow for calculating the 90% CI in a 2×2 crossover design:

1. Log-transform the individual subject values for C_max, AUC_0-t, etc.
2. Calculate the difference in means (log-transformed) between test and reference.
3. Estimate the standard error (SE) from the residual mean square of ANOVA.
4. Calculate the 90% CI using:
   CI = (mean difference) ± t_α,df × SE
5. Exponentiate the lower and upper bounds to return to the original scale.

Dummy Example of CI Calculation

Since both 90% CIs fall within the 80.00–125.00% interval, the formulations are considered bioequivalent.

Regulatory Acceptance Range and Adjustments

The default acceptance range for the 90% CI is 80.00–125.00%. However, exceptions apply:

• Narrow Therapeutic Index (NTI) drugs: Some agencies, such as the EMA, tighten this range to 90.00–111.11% for AUC.
• Highly Variable Drugs (HVDs): The range may be widened using reference-scaled average bioequivalence (RSABE), especially when within-subject variability (CV%) exceeds 30%.

Refer to current HVD-specific guidelines from ISRCTN for more information on scaled acceptance criteria.

Visualizing Confidence Interval Decision Making

A graphical representation often helps illustrate the decision process:

• If the 90% CI lies entirely within 80–125%, then BE is established.
• If the CI crosses the boundary (e.g., 78–122%), then BE is not established—even if the GMR is close to 100%.

Common Misconceptions About CI in BE Studies

• Misconception: Passing one parameter (e.g., AUC) is enough.
  Reality: All predefined PK parameters must meet CI criteria.
• Misconception: Point estimate within limits is sufficient.
  Reality: CI, not point estimate alone, determines BE.
• Misconception: CI can be calculated on raw data.
  Reality: Log-transformed data is mandatory.

Statistical Tools and Software for CI Estimation

Several software packages are validated for calculating 90% CIs in BA/BE studies:

• WinNonlin® (Phoenix): Industry standard with validated statistical engines
• SAS®: Used for complex mixed-model designs and regulatory submissions
• R (Package: bear): Open-source tool for academic and small sponsors

Case Study: Failed BE Due to CI Just Missing the Limit

A study evaluating a generic extended-release antidepressant showed a C_max GMR of 94%, with a 90% CI of 79.6% to 112.8%. Despite a good match on AUC, the lower CI limit fell just below 80%, leading to a failed BE conclusion. The sponsor later adjusted the formulation and repeated the study successfully.

Conclusion: CI Is the Regulatory Benchmark for Bioequivalence

The 90% confidence interval rule is not a statistical preference—it’s a regulatory mandate for establishing therapeutic equivalence. By understanding its theoretical foundation, calculation methods, and potential adjustments, pharma and clinical professionals can design, analyze, and interpret BA/BE studies with precision and compliance. A well-constructed CI speaks louder than point estimates or p-values when it comes to regulatory approvals.